Literature DB >> 17234900

Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro.

Zhihua Xie1, Susan V Westmoreland, Mary E Bahn, Guo-Lin Chen, Hong Yang, Eric J Vallender, Wei-Dong Yao, Bertha K Madras, Gregory M Miller.   

Abstract

Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor that directly responds to endogenous monoamines as well as amphetamine-related psychostimulants, including methamphetamine. In the present study, we demonstrate TAAR1 mRNA and protein expression in rhesus monkey brain regions associated with monoaminergic systems, variable cellular distribution of TAAR1 in rhesus monkey brain, and TAAR1 coexpression with the dopamine transporter (DAT) in a subset of dopamine neurons in both rhesus monkey and mouse substantia nigra. On this basis, we evaluated rhesus monkey TAAR1 activation by different compounds and its functional relation with monoamine transporters and the dopamine D2 receptor (D2) short isoform (D2s) autoreceptor in vitro using a cAMP response element-luciferase assay. TAAR1 activation by monoamines and amphetamine-related compounds was greatly enhanced by coexpression of dopamine, norepinephrine, or serotonin transporters, and the activation enhancement was blocked by monoamine transporter inhibitors. This enhancement did not occur in control experiments in which the dopamine D1 receptor (D1) was substituted for TAAR1. Furthermore, activation of TAAR1 by dopamine was completely inhibited by D2s when coexpressed with TAAR1, and this inhibition was blocked by the D2 antagonist raclopride. Last, dopamine activation of TAAR1 could induce c-FOS-luciferase expression but only in the presence of DAT, whereas dopamine activation of D1 resulted in equivalent c-FOS expression in the presence or absence of DAT. Together, these data reveal a broad agonist spectrum for TAAR1, a functional relation of TAAR1 with monoamine transporters and D2s, and a mechanism by which D2 receptor drugs can influence brain monoaminergic function and have efficacy through affecting TAAR1 signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234900     DOI: 10.1124/jpet.106.116863

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  54 in total

1.  Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1.

Authors:  Cindy Achat-Mendes; Laurie J Lynch; Katherine A Sullivan; Eric J Vallender; Gregory M Miller
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

2.  Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).

Authors:  Gregory M Miller
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

Review 3.  The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.

Authors:  Gregory M Miller
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

Review 4.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

5.  A decade of pharma discovery delivers new tools targeting trace amine-associated receptor 1.

Authors:  Katie R Tallman; David K Grandy
Journal:  Neuropsychopharmacology       Date:  2012-11       Impact factor: 7.853

6.  Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells.

Authors:  Ada Ledonne; Mauro Federici; Michela Giustizieri; Mauro Pessia; Paola Imbrici; Mark J Millan; Giorgio Bernardi; Nicola B Mercuri
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 7.  Monoamines in glioblastoma: complex biology with therapeutic potential.

Authors:  Seamus Patrick Caragher; Robert Raymond Hall; Riasat Ahsan; Atique U Ahmed
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

8.  Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs.

Authors:  Eric J Vallender; Zhihua Xie; Susan V Westmoreland; Gregory M Miller
Journal:  BMC Evol Biol       Date:  2010-02-18       Impact factor: 3.260

Review 9.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

10.  Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood.

Authors:  Chloe J Jordan; Carley Lemay; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2016-09-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.